Brief: Cereno Scientific Signs Agreement With Fluidda
30/09/2024 07:17
Sept 30 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* SIGNS AGREEMENT WITH FLUIDDA, TO EVALUATE THE IMPACT OF
ITS HDAC
INHIBITOR CS1 ON REVERSE REMODELING OF PULMONARY VESSELS IN
PATIENTS WITH PAH
Source text for Eikon: ID:nWkr12yWxg
Further company coverage: CRNOSb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln